Dear Editor,The atypical chemokine receptor ACKR3 has recently been reported to act as an opioid scavenger with unique negative regulatory properties towards different families of opioid peptides.Here,we show that con...Dear Editor,The atypical chemokine receptor ACKR3 has recently been reported to act as an opioid scavenger with unique negative regulatory properties towards different families of opioid peptides.Here,we show that conolidine,a natural analgesic alkaloid used in traditional Chinese medicine,targets ACKR3,thereby providing additional proof of a correlation between ACKR3 and pain modulation and opening alternative therapeutic avenues for the treatment of chronic pain.展开更多
基金This study was supported by the Luxembourg Institute of Health(LIH),Luxembourg National Research Fund(Pathfinder"UH383",INTER/FWO"Nanokine"grant 15/10358798,INTER/FNRS grants 20/15084569,PoC"Megakine"19/14209621 and PRIDE 11012546-Nextlmmune"and 14254520""TRON")F.R.S.-FNRS-Tvie(grants 7.4593.19,7.4529.19,and 7.8504.20)+1 种基金by RTI International Internal Research and Development Funds(awarded to O.N.)M.M.and C.P.are Luxembourg National Research Fund PhD fellows(grants AFR-3004509 and AFR-14616593).
文摘Dear Editor,The atypical chemokine receptor ACKR3 has recently been reported to act as an opioid scavenger with unique negative regulatory properties towards different families of opioid peptides.Here,we show that conolidine,a natural analgesic alkaloid used in traditional Chinese medicine,targets ACKR3,thereby providing additional proof of a correlation between ACKR3 and pain modulation and opening alternative therapeutic avenues for the treatment of chronic pain.
